Investors Are Urged To Participate In An Investigation Into Blueprint Medicines Corporation's Potential Securities Law Violations
The Schall Law Firm is investigating potential securities law violations by Blueprint Medicines (NASDAQ: BPMC). The investigation centers on whether Blueprint issued false or misleading statements to investors. On August 17, 2022, Blueprint announced top-line results from Part 2 of its PIONEER clinical trial for AYVAKIT® (avapritinib). The company revealed that the absolute improvement in symptom score decreased from 19.7 in Part 1 to 15.6 in Part 2. This news caused Blueprint's stock to fall by 10% on the same day.
Shareholders who suffered losses are encouraged to contact the Schall Law Firm to discuss their rights. The firm specializes in securities class action lawsuits and shareholder rights litigation. It's important to note that the class in this case has not yet been certified, and affected shareholders are not currently represented by an attorney unless they take action.
Lo studio legale Schall sta indagando possibili violazioni delle leggi sui titoli da parte di Blueprint Medicines (NASDAQ: BPMC). L'indagine si concentra su se Blueprint abbia emesso dichiarazioni false o ingannevoli agli investitori. Il 17 agosto 2022, Blueprint ha annunciato i risultati preliminari della Parte 2 del suo studio clinico PIONEER per AYVAKIT® (avapritinib). L'azienda ha rivelato che il miglioramento assoluto del punteggio dei sintomi è diminuito da 19,7 nella Parte 1 a 15,6 nella Parte 2. Questa notizia ha causato un crollo del 10% delle azioni di Blueprint nello stesso giorno.
Gli azionisti che hanno subito perdite sono invitati a contattare lo studio legale Schall per discutere dei propri diritti. Lo studio è specializzato in cause legali collettive sui titoli e contenziosi sui diritti degli azionisti. È importante notare che la classe in questo caso non è ancora stata certificata, e gli azionisti interessati non sono attualmente rappresentati da un avvocato a meno che non intraprendano un'azione.
El bufete de abogados Schall está investigando posibles violaciones de la ley de valores por parte de Blueprint Medicines (NASDAQ: BPMC). La investigación se centra en si Blueprint emitió declaraciones falsas o engañosas a los inversores. El 17 de agosto de 2022, Blueprint anunció los resultados preliminares de la Parte 2 de su ensayo clínico PIONEER para AYVAKIT® (avapritinib). La empresa reveló que la mejora absoluta en el puntaje de síntomas disminuyó de 19.7 en la Parte 1 a 15.6 en la Parte 2. Esta noticia provocó que las acciones de Blueprint cayeran un 10% el mismo día.
Se alienta a los accionistas que sufrieron pérdidas a comunicarse con el bufete de abogados Schall para discutir sus derechos. El bufete se especializa en demandas colectivas de valores y litigios sobre los derechos de los accionistas. Es importante señalar que la clase en este caso aún no ha sido certificada, y los accionistas afectados no están actualmente representados por un abogado a menos que tomen medidas.
샬 법률사무소는 Blueprint Medicines(NASDAQ: BPMC)의 잠재적인 증권법 위반을 조사하고 있습니다. 해당 조사는 Blueprint가 투자자에게 거짓 또는 오해의 소지가 있는 진술을 했는지 여부에 중점을 두고 있습니다. 2022년 8월 17일, Blueprint는 AYVAKIT®(avapritinib)에 대한 PIONEER 임상시험 2부의 최종 결과를 발표했습니다. 회사는 증상 점수의 절대적인 개선률이 1부의 19.7에서 2부의 15.6으로 감소했다고 밝혔습니다. 이러한 소식은 같은 날 Blueprint의 주가가 10% 하락하게 만들었습니다.
손실을 입은 주주들은 자신의 권리에 대해 논의하기 위해 샬 법률사무소에 연락해야 합니다. 이 법무법인은 증권 집단 소송 및 주주 권리 소송을 전문으로 합니다. 이 사건의 경우 클래스가 아직 인증되지 않았으며, 영향을 받은 주주들은 조치를 취하지 않는 한 현재 변호사에 의해 대리받지 않고 있다는 점에 유의해야 합니다.
Le cabinet d'avocats Schall enquête sur d'éventuelles violations des lois sur les valeurs mobilières de la part de Blueprint Medicines (NASDAQ: BPMC). L'enquête porte sur la question de savoir si Blueprint a émis des déclarations fausses ou trompeuses à l'intention des investisseurs. Le 17 août 2022, Blueprint a annoncé les résultats préliminaires de la Partie 2 de son essai clinique PIONEER pour AYVAKIT® (avapritinib). L'entreprise a révélé que l'amélioration absolue du score des symptômes a diminué de 19,7 dans la Partie 1 à 15,6 dans la Partie 2. Cette nouvelle a provoqué une chute de 10 % des actions de Blueprint le même jour.
Les actionnaires ayant subi des pertes sont encouragés à contacter le cabinet d'avocats Schall pour discuter de leurs droits. Le cabinet est spécialisé dans les actions collectives en valeurs mobilières et les litiges concernant les droits des actionnaires. Il est important de noter que la classe dans ce cas n'a pas encore été certifiée et que les actionnaires concernés ne sont pas actuellement représentés par un avocat, à moins qu'ils n'agissent.
Die Schall Kanzlei untersucht potenzielle Verstöße gegen das Wertpapierrecht durch Blueprint Medicines (NASDAQ: BPMC). Die Untersuchung konzentriert sich darauf, ob Blueprint falsche oder irreführende Aussagen an Investoren gemacht hat. Am 17. August 2022 gab Blueprint die Gesamtergebnisse der Phase 2 seiner PIONEER-Studie für AYVAKIT® (avapritinib) bekannt. Das Unternehmen gab bekannt, dass die absolute Verbesserung der Symptompunkte von 19,7 in Phase 1 auf 15,6 in Phase 2 gesunken ist. Diese Nachricht führte dazu, dass die Aktien von Blueprint am selben Tag um 10% fielen.
Aktionäre, die Verluste erlitten haben, werden aufgefordert, sich mit der Schall Kanzlei in Verbindung zu setzen, um ihre Rechte zu besprechen. Die Kanzlei hat sich auf Wertpapier-Kollektivklagen und Klagen zu Aktionärsrechten spezialisiert. Es ist wichtig zu beachten, dass die Klasse in diesem Fall noch nicht zertifiziert wurde und betroffene Aktionäre derzeit nicht von einem Anwalt vertreten werden, es sei denn, sie ergreifen Maßnahmen.
- None.
- None.
LOS ANGELES, CA / ACCESSWIRE / August 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or "the Company") (NASDAQ:BPMC) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Blueprint announced top-line results from the registrational Part 2 of its PIONEER clinical trial of AYVAKIT® (avapritinib) on August 17, 2022. The Company disclosed that the absolute improvement in the symptom score fell from 19.7 in the first part of the trial to 15.6 in part 2. Based on this news, shares of Blueprint fell by
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com
SOURCE: The Schall Law Firm
View the original press release on accesswire.com
FAQ
What is the Schall Law Firm investigating regarding Blueprint Medicines (BPMC)?
What caused Blueprint Medicines (BPMC) stock to drop 10% on August 17, 2022?
How can affected shareholders of Blueprint Medicines (BPMC) participate in the investigation?
Has a class been certified for the Blueprint Medicines (BPMC) investigation?
